1-(4-chloro-phenyl)-3-[2-((3S)-3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylmethyl]-urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 1-(4-chloro-phenyl)-3-[2-((3S)-3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylmethyl]-urea
• 英文别名: 1-(4-chlorophenyl)-3-[[2-[(3S)-3-methyl-2,6-dioxopiperidin-3-yl]-1,3-dioxoisoindol-5-yl]methyl]urea
• 化学式: C₂₂H₁₉ClN₄O₅
• 分子量: 454.87
• InChiKey: BLDXZVBWFKPNPA-QFIPXVFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  32
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-aminomethyl-2-[(3S)-3-methyl-2,6-dioxo-piperidin-3-yl]-isoindole-1,3-dione hydrochloride 、 对氯苯异氰酸酯 生成 1-(4-chloro-phenyl)-3-[2-((3S)-3-methyl-2,6-dioxo-piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-ylmethyl]-urea
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• 5-SUBSTITUTED ISOINDOLINE COMPOUNDS
  申请人：CELGENE CORPORATION

  公开号：US20150005303A1

  公开（公告）日：2015-01-01

  This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

  本发明涉及5-取代的异吲哚啉化合物，以及其药物可接受的盐，溶剂化物，立体异构体和前药。本发明还揭示了这些化合物的使用方法和制药组合物。
• 5-substituted isoindoline compounds
  申请人：CELGENE CORPORATION

  公开号：EP2749559A1

  公开（公告）日：2014-07-02

  The present invention relates to 5-substituted isoindoline compounds of formula (III) or formula (IV) wherein R10, R11, R13, R14, X and Y are as defined herein; or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof. The present invention also relates to a pharmaceutical composition of the compounds of the invention. The present invention also relates to a compound of the invention for use in treating, managing or preventing disease conditions as disclosed herein.

  本发明涉及式 (III) 的 5-取代异吲哚啉化合物 或式（IV） 其中R10、R11、R13、R14、X和Y如本文所定义；或其药学上可接受的盐、溶液、立体异构体或原药。本发明还涉及本发明化合物的药物组合物。本发明还涉及用于治疗、控制或预防本文所公开的疾病状况的本发明化合物。
• Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
  申请人：Celgene Corporation

  公开号：US10034872B2

  公开（公告）日：2018-07-31

  Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of an immunomodulatory compound, e.g., lenalidomide or pomalidomide with an anti-CS1 antibody, e.g., elotuzumab in patients who have received autologous stem cell transplantation.

  本文公开了治疗、预防和/或控制多发性骨髓瘤的方法。具体方法包括在接受了自体干细胞移植的患者中使用免疫调节化合物，如来那度胺或泊马度胺与抗CS1抗体，如艾洛妥珠单抗。
• METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
  申请人：Signal Pharmaceuticals, LLC

  公开号：US20140314752A1

  公开（公告）日：2014-10-23

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of an IMiD® immunomodulatory drug to a patient having a cancer.
• US8877780B2
  申请人：——

  公开号：US8877780B2

  公开（公告）日：2014-11-04